Tina C. Young
University of California, Los Angeles(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, CAR-T cell therapy research, Immunotherapy and Immune Responses, Mathematical Biology Tumor Growth
Most-Cited Works
- → Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study(2016)952 cited
- → Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma(2016)290 cited
- → Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC(2018)176 cited
- → TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma(2021)130 cited
- → Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)(2019)100 cited
- → Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)(2019)44 cited
- → Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.(2019)35 cited
- → Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.(2015)25 cited
- → Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma(2019)17 cited
- → OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update(2017)15 cited